This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elliott, S. L.
Right arrow Articles by Bharadwaj, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elliott, S. L.
Right arrow Articles by Bharadwaj, M.

 Previous Article  |  Next Article 

Journal of Virology, February 2008, p. 1448-1457, Vol. 82, No. 3
0022-538X/08/$08.00+0     doi:10.1128/JVI.01409-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis{triangledown}

Suzanne L. Elliott,1 Andreas Suhrbier,1* John J. Miles,1 Greg Lawrence,1 Stephanie J. Pye,1 Thuy T. Le,1 Andrew Rosenstengel,1 Tam Nguyen,1 Anthony Allworth,2 Scott R. Burrows,1 John Cox,3 David Pye,3 Denis J. Moss,1 and Mandvi Bharadwaj1*

Australian Centre for Vaccine Development, Queensland Institute of Medical Research, Brisbane, Australia,1 Infectious Disease Unit, Royal Brisbane Hospital, Brisbane, Australia,2 CSL Limited, Melbourne, Australia3

Received 28 June 2007/ Accepted 17 October 2007

A single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8+ T-cell peptide epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGRAYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720. FLRGRAYGL-specific responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor Vβ CDR3 sequence that is found in FLRGRAYGL-specific T cells from most EBV-seropositive individuals could also be detected in the peripheral blood of vaccine recipients. The vaccine was well tolerated, with the main side effect being mild to moderate injection site reactions. After a 2- to 12-year follow-up, 1/2 placebo vaccinees who acquired EBV developed infectious mononucleosis, whereas 4/4 vaccinees who acquired EBV after completing peptide vaccination seroconverted asymptomatically. Single-epitope vaccination did not predispose individuals to disease, nor did it significantly influence development of a normal repertoire of EBV-specific CD8+ T-cell responses following seroconversion.

* Corresponding author. Mailing address for A. Suhrbier: Queensland Institute of Medical Research, P.O. Royal Brisbane Hospital, Queensland 4029, Australia. Phone: 61-7-33620415. Fax: 61-7-33620107. E-mail: andreasS{at}qimr.edu.au. Mailing address for M. Bharadwaj: Dept. of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3052, Australia. Phone: 61-3-83449911. Fax: 61-3-93471540. E-mail: mandvi{at}unimelb.edu.au

{triangledown} Published ahead of print on 21 November 2007.

Journal of Virology, February 2008, p. 1448-1457, Vol. 82, No. 3
0022-538X/08/$08.00+0     doi:10.1128/JVI.01409-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Stevenson, P. G., Simas, J. P., Efstathiou, S. (2009). Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4. J. Gen. Virol. 90: 2317-2330 [Abstract] [Full Text]  
  • Venturi, V., Chin, H. Y., Asher, T. E., Ladell, K., Scheinberg, P., Bornstein, E., van Bockel, D., Kelleher, A. D., Douek, D. C., Price, D. A., Davenport, M. P. (2008). TCR {beta}-Chain Sharing in Human CD8+ T Cell Responses to Cytomegalovirus and EBV. J. Immunol. 181: 7853-7862 [Abstract] [Full Text]  
  • Gurer, C., Strowig, T., Brilot, F., Pack, M., Trumpfheller, C., Arrey, F., Park, C. G., Steinman, R. M., Munz, C. (2008). Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112: 1231-1239 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»